Abstract Hepatitis C virus (HCV) is a blood borne, circular and positive single stranded virus with high spread rates. With the passage of time the frequency of HCV is increasing in different parts of the world. HCV is a major cause, which may end in liver cirrhosis and hepatocellular carcinoma. HCV has six main genotypes with many subtypes, which have variable sequence homology with each other. Symptoms can appear anytime from 2 weeks to 6 months, which include jaundice, fatigue, gray-colored stool, joint pain, belly pain, weakness, anorexia, itchy skin and dark urine. Genotyping is more significant for planning of HCV treatment period and helps to cure HCV infections. For the quantification and identification of hepatitis C virus-ribonucleic acid, many molecular techniques are performed; the most significant are HCV ELISA, quantitative HCV-RNA PCR and recombinant immunoblot assay. PCR is the major technique targeting 5 0 untranslated region (UTR). HCV can be transmitted by contaminated blood, ear and nose piercing and contaminated medical instruments. To overcome the rate of HCV, guidance should be provided to make aware the persons about risk factors, transmission and prevention. Discovery and designing of new therapies and vaccines to overcome this disease are the necessity of the present era. Four types of vaccines such as vector vaccines, peptide vaccines, DNA vaccines and recombinant protein vaccines are available in clinical trials.
History and structure of hepatitis C virus
Hepatitis C virus (HCV) is an infectious pathogen causing great damage to the liver [1] . HCV was initially isolated from the serum of an individual with non-A, non-B hepatitis discovered by Choo et al. in 1989 [2] . Briefly after cloning of HCV, the newly discovered virus was found to be the main reason of about 90% of non-A, non-B hepatitis in the US [3] . It is the most common cause of chronic liver disease ending in liver cirrhosis and hepatocellular carcinoma [4] . Globally, it is the main cause of death and morbidity [5] with major global health issues affecting 180 million individuals of the world and 10 million people in Pakistan [6] . Every year about 3-4 million individuals are affected by HCV [7] . About 27% individuals are infected and have cirrhosis and 25% have hepatocellular carcinoma [8] .
HCV is enveloped, small circular, positive-sense and single stranded ribonucleic acid (RNA) virus from genus Hepacivirus, family Flaviviridae with a diameter of 50 nm [9] .
The total length of RNA genome is about 9.6 kb with one open reading frame (ORF) and 5 0 and 3 0 untranslated regions (UTRs) at both edges [10] . 5 0 UTR is a more conserved part of HCV genome, which helped in evolutionary studies and genotyping [11, 12] .
The open reading frame encodes a polyprotein, which is comprised of 10 viral proteins named as Core (C), E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B (Fig. 1) . The 3 structural proteins are C, E1 and E2, while the 7 nonstructural proteins are P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B [13] . Among structural proteins, core protein (21 kDa) consists of 191 amino acids, which are important components of nucleocapsid. Core protein modulates gene transcription, cell death, cell proliferation and interference metabolism leading to oxidative stress, liver steatosis and finally hepato cellular carcinoma (HCC). HCV envelope proteins E1 and E2 are generally glycosylated and have played a major role in cell entry. Protein P7 is responsible for ion channel and virus assembly [14] . The proteins NS3 serine protease and NS5B played a major role in viral replication. Main targets for antiviral drug development are structural proteins, NS5B RNA-dependent RNA polymerase and NS3 serine protease [15] .
HCV has six main genotypes (1-6) with multiple subtypes. The most worldwide epidemic genotypes are 1-3. Genotyping is most significant for planning of HCV treatment and helps to cure HCV infections [16] . Due to the high prevalence and increasing rate of HCV infected persons day by day, the aim of the present review was to collect information about HCV virus, its symptoms and cure by awareness on utilization of sterilized instruments/syringes in health care centers, preparing antiviral drugs, introducing new therapies and vaccines for HCV control.
Frequency of HCV genotypes and infections
HCV-1, HCV-2 and HCV-3 are distributed worldwide, whereas HCV-4, HCV-5 and HCV-6 are present in certain areas of the globe. The frequency of HCV is highest in few countries and areas, such as in Europe 25 million cases are HCV positive [17] . In Pakistan, HCV is 5% prevalent [18] , whereas 5-9% prevalence is detected in Khyber Pakhtunkhwa province of Pakistan [19] causing liver cancer [20] . HCV-4 is prevalent among Middle East and Africa causing more than 80% of HCV infections and has recently spread to several European countries. Egypt has the highest prevalence of HCV worldwide (15%) and the highest frequency of HCV-4 responsible for almost 90% of infections and a major cause of chronic hepatitis, liver cirrhosis, hepatocellular carcinoma and transplantation in the country. Although HCV-4 is the cause of about 20% of the 170 million cases of hepatitis C in the world [21] . In the United States, the number of new cases of HCV infection has declined from a peak of 200,000 annually to about 17,000 in 2007. Up to 85% of newly infected people failed to eliminate the virus and become chronically infected. HCV infection is the leading cause of liver transplantation in the US and is a risk factor for liver cancer [22] .
Acute infection and chronic infection
Acute hepatitis C infection is infrequently diagnosed as the majority of acutely infected individuals are asymptomatic. In the transfusion setting, acute HCV infection has been known to be 70-80% asymptomatic and 20-30% of adults showed clinical symptoms [23, 24] . Chronic hepatitis C is marked by the persistence of HCV-RNA in the blood for at least 6 months after onset of acute infection. HCV is self-limiting in only 15-25% of patients, whom HCV-RNA in the serum becomes undetectable and ALT levels returned to normal. Approximately 75-85% of infected patients do not clear the virus by 6 months and chronic hepatitis developed in them. The rate of chronic HCV infection is affected by many factors, including the age at time of infection, gender, ethnicity and development of jaundice during acute infection [25] .
Route of transmission and symptoms of HCV
HCV can be transmitted through intravenous drug use (IVDU), blood to blood contact, birth to an infected mother, blood products, organ transplantation, use of unsterilized injection needles, use of unsterilized instruments for nose and ear piercing or tattoos (Table 1 ) and these reasons are the major sources of transmission of HCV in Pakistan [26, 27] . In developing countries HCV is transmitted by IVDU, sexual exposure and blood products [26, 28] . Virus cannot be transmitted from one person to other by sharing drink or food with an infected individual [29] .
Symptoms can appear anytime from 2 weeks to 6 months after a person is infected with the virus. Symptoms include jaundice, fatigue, gray-colored stool, joint pain, belly pain, weakness, anorexia, itchy skin and dark urine. Mild cognitive problems and fatigue are the major symptoms of chronic hepatitis C [25] . A study conducted in Egypt showed the symptoms of HCV including history of fatigue, diarrhea and abdominal pains. Another study performed on 77 Spanish and Italian children revealed that HCV was generally asymptomatic among them [30] .
Diagnosis and genotyping of HCV
For the quantification and detection of HCV-RNA, many molecular biology techniques are described ( Table 2 ). The significant technique is PCR targeting 5 0 UTR region [31] . Several tests are used to diagnose the hepatitis C virus, which include HCV antibody enzyme immunoassay (ELISA), quantitative HCV-RNA PCR and recombinant immunoblot assay [32] . HCV-RNA by PCR is the quickest and most informative method for HCV detection, while long infection time is required to detect virus using antibodies [33] . The hepatitis C diagnosis mostly depends on serological assay and HCV-RNA. For the epidemiology surveillance and screening, confirmatory recombinant immunoblot assay and ELISA are performed for the identification of HCV-specific antibodies (anti-ssHCV). For the identification of viral genome and confirmation of active infection, qualitative polymerase chain reaction is used. This methodology is quite effective in monitoring disease activity and treatment response [34] .
Bioinformatics analysis and databases for HCV
A study conducted in Saudi Arabia on HCV positive samples by sequencing their 5 0 UTR regions revealed the identification of new HCV isolates. For sequencing and amplification, specific primers were used which target the 5 0 UTR region. In this study most of the HCV isolates were G4 (76.4%) and small 
Prevalence of HCV genotypes
HCV prevalence is variable in various regions of the world and among different groups of a community [38] . Genotype 1a is most prevalent in the United States and Northern Europe (Table 1) , while 1b is the most common genotype worldwide [39] . In Europe and Japan, genotype 2a and 2b are most prevalent, while 2c subtype is most frequent in Northern Italy. In Africa and Middle East, the most prevalent genotype is 4 (Table 3) . Genotype 5 and 6 are most common in South Africa and Asia [40, 41] . Genotype 3a is most common in Pakistan in comparison to 3b and 1a [42] . In the nucleotide composition of genome, the six main genotypes are about 30-35% different from one another, while approximately 20-25% subtypes are different from each other [39] . Genotype 1 is more common in the world including 83.4 million cases (42.6% of total HCV cases), of which about 1/3 are present in East Asia. After genotype 1, genotype 3 is more common worldwide including 54.3 million cases (30.1% of HCV cases). G-2, G-4 and G-6 are responsible for a total 22.8% of whole cases, while G-5 includes the remaining percentage (>1%). In most countries G-1 and G-3 are most prevalent in comparison to other genotypes while G-4 and G-5 are prevalent in less developed countries [44] . Hospital based studies of various Pakistani cities revealed that the prevalence rate of HCV is 5.31% (Islamabad), 2.45% (Rawalpindi), 4.0% (Multan), 20.89% (Mardan), 5% (Faisalabad), 4-6% (Buner) and 25.7% (Northern areas) [34, 45] . A similar study conducted in Bangladesh revealed that G-3 was the most prevalent genotype in comparison to other genotypes [16] .
A study conducted on HCV-RNA positive patients in Isfahan province (Iran) revealed that the common rate of HCV genotypes was 3a (61.2%), 1a (29.5%), 1b (5.1%), genotype 2 (2%) and mixed types 1a + 3a (2%) [46] . In other studies type 3 cases are completely represented by subtype 3a, while type 4 cases (52.3%) are represented by subtype 4c and 4d in Italy [47] . Several other studies confirmed the high prevalence of genotype 1a and 1b in HCV patients from different parts of the world [48] [49] [50] .
HCV treatment by different therapies, vaccines and local remedies
General treatment is recommended for HCV patients with complications in the liver (Table 4) . For the treatment of chronic hepatitis C, the combination of pegylated interferon alpha-2a or 2b and ribavirin may be used. The endpoint of HCV treatment is sustained virological response (SVR), defined by an undetectable HCV-RNA in serum with a sensitive assay (lower limit of detection of 10-50 IU/mL) 24 weeks after the end of treatment. Genotype 2 and 3 infected patients require 24 weeks of treatment and a low dose of ribavirin (800 mg daily). In contrast, genotype 1, 4, 5 and 6 infected individuals requires 48 weeks of treatment and a body weight based dose of ribavirin (1000-1400 mg daily) [35] . A combination of treatment is administered for a period of 24-48 weeks depending on the HCV genotype (Table 4 ). This treatment includes ribavirin and pegylated interferon alpha in combination [32] . Around 70% and 80% cure rates were achieved for genotype 2 and 3 respectively and 45-70% for other genotypes [51] . Recently two latest therapeutic agents called as boceprevir and telaprevir are introduced in few countries, which are protease inhibitors and control HCV [52] . The combination of telaprevir or boceprevir with pegylated interferon-alpha and ribavirin is highly beneficial in controlling genotype 1 [53] . The treatment of HCV is more effective during the first six months than once it becomes chronic. If new infection develops in a person and remained uncontrolled till 8-12 weeks, pegylated interferon is strongly recommended for a period of 24 weeks to control the virus [33] . HCV genotype 1, 4, 5 or 6 and their associated diseases are controlled by administrating a combination of Sofosbuvir with ribavirin and interferon, which was found to be 90% effective against the viral diseases [54] . In Japan during December 2013, pegylated-interferon, simeprevir (SMV) and ribavirin (RBV) triple combination therapy was used to treat this disease specially genotype 1 in clinical practice [55] . In the patients of genotype 1 (42-46%), G-2 and G-3 (76-82%), a significantly increased response was detected for polyethylenglycol (PEG)-conjugated interferon alpha in comparison to the conventional interferon alpha [56] (Table 4) .
Several alternative treatments or traditional remedies are used by infected people to control HCV. These include the use of Quranic verses (Dam) and other alternative and homeopathic medicines to cure it due to high costs of conventional medicines. Around 50% individuals follow alternative medicines and 65% are using both conventional and unconventional medicines [64] . Some infected patients try herbal medicine to recover from virus such as Proanthocyandin obtained from leaves of blue berry, Rhodiolakirilowii (Regel), Maxim and laccase obtained from oyster mushroom but no affective reports are documented [65] .
Management of HCV in Pakistan
Pakistan is a developing country with less medical facilities available for its citizens. Around 75% Pakistanis are living below poverty line and cannot afford expensive medicines and drugs. More than 80 different interferon's brands are available in Pakistan, but they are out of reach of common people due to their high costs. The ''Prime Minister Program for prevention and control of hepatitis'' was launched in recent years and during 2006-2008, around 20,000 patients received free interferon treatment but the treated cases were only 0.01% of the total cases. After 12 years of this program, still 3/4 patients are away to receive this treatment. For Pakistani patients, currently a combination of ribavirin and interferon alpha is recommended, which showed high viral control response [34, 42] .
A higher sustained virological response (SVR) rate was significantly detected in Pashtoons (69.2%) in comparison to Punjabi (45.5%), Sindhi (45.5%) and Balouchi (50%) tribes after administering INF-alpha plus ribavirin to patients. The highest SVR in patients with HCV was genotype 2 (69.7%), followed by G-3 (57.3%), while the lowest SVR was investigated in G-1 infection (24.3%) [42] . Another study comprising 190 patients from both sexes between age limits 20-68 years revealed that G-3 (48.9%) was the most prevalent genotype in comparison to G-1 (42.6%). Of the overall infected persons, the response rate was 49.6%, 68.8% and 62.4% in G-1, G-2 and G-3 respectively [66] .
Vaccines used for HCV control
Four types of vaccines (Table 5 ) are available in clinical trials naming vector vaccines, peptide vaccines, recombinant protein vaccines and DNA vaccines [67] . These vaccines are formed to induce targeting envelope part of the pathogen, T-cell responses and targeting nonstructural proteins [68] . Conserved HCV core protein vaccine is used with adjuvant made up of cholesterol, saponin and phospholipid and is known as ISCOMATRIX. The vaccine is well tolerated and showed a well developed humoral response [69] . According to a Japanese study, a peptide obtained from HCV core section (C35-C44) was used in Phase I. Of the 26 infected persons, 3 responded to standard therapy and 23 were non responders to ribavirin and pegylated-interferon [70] . Adenovirus vectors are Phase I vaccines. The two adenoviral vectors are Ad6 and Adch3, displaying NS3 and NS5B proteins (Table 5 ) [71] . Good tolerated, of 6 only 4 patients are receiving high doses [72] 11. Side effects of IFN therapy and ribavirin
In the starting week of IFN treatment, flu like symptoms can occur. Further side effects may be arthralgia, chill, headaches, fever and myalgia. Negative effects of neuropsychiatric include severe fatigue, irritability and severe depression, which may lead to suicide attempts [73] . A major side effect of ribavirin is hemolytic anemia [59] .
Prevention and management of HCV diseases
Although few patients are cured at initial stages but the activated virus after some time will be uncontrollable and can cause human deaths. No proper vaccine and antiviral drugs are available to control 100% HCV. Our initial focus should be on prevention including safe injection practices in hospitals and another places, safe blood supply and guidance to the injection drug abuser or intravenous drug users about the risk of HCV. Health education is necessary to minimize the rate of HCV. Special programs should be launched to make aware the public on risk factors, transmission and prevention of the disease. Safe blood test and other laboratory tests are necessary for an early diagnosis of HCV [74] .
Conclusion
HCV is a major global health issue affecting several individuals around the globe. The prevalence of HCV genotypes varies all over the world due to virus mutation, route of infection and population analysis. Monthly or yearly blood tests should be necessary for the diagnosis of HCV. In a majority of people, HCV causing liver cirrhosis and hepatocellular carcinoma cannot be diagnosed at early stages. New therapies with fewer or no side effects should be introduced to cure the virus. Guidance plays an important role in preventing people from this infection. Awareness seminars regarding the risk factor of HCV infection should be regularly arranged and discovery of new vaccines by scientists is of utmost importance to overcome this disease.
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